Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Published:2023-01 Issue:1 Volume:24 Page:77-90
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Johnston Stephen R D,Toi Masakazu,O'Shaughnessy Joyce,Rastogi Priya,Campone Mario,Neven Patrick,Huang Chiun-Sheng,Huober Jens,Jaliffe Georgina Garnica,Cicin Irfan,Tolaney Sara M,Goetz Matthew P,Rugo Hope S,Senkus Elzbieta,Testa Laura,Del Mastro Lucia,Shimizu Chikako,Wei Ran,Shahir Ashwin,Munoz Maria,San Antonio Belen,André Valérie,Harbeck Nadia,Martin Miguel

Publisher

Elsevier BV

Subject

Oncology

Reference27 articles.

1. 20-year risks of breast-cancer recurrence after stopping endocrine therapy at 5 years;Pan;N Engl J Med,2017

2. A real-world US study of recurrence risks using combined clinicopathological features in HR-positive, HER2-negative early breast cancer;Sheffield;Future Oncol,2022

3. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE);Johnston;J Clin Oncol,2020

4. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study;Harbeck;Ann Oncol,2021

5. Indianapolis,2021

Cited by 232 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world prevalence, treatment and survival of “high risk” early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry;The Breast;2024-12

2. Abemaciclib increases the risk of venous thromboembolism in breast cancer: Integrate meta-analysis, pharmacovigilance database analysis, and in vitro validation;Cancer Treatment Reviews;2024-11

3. Parp-inhibitors in the therapeutic landscape of breast cancer patients with BRCA1 and BRCA2 pathogenic germline variants: An Italian consensus paper and critical review;Cancer Treatment Reviews;2024-11

4. Adjuvant endocrine therapy choices in premenopausal patients with hormone receptor-positive early breast cancer: Insights from the prospective GIM23-POSTER study;The Breast;2024-10

5. Questionnaire survey and analysis of drug clinical research implementation capabilities of breast cancer treatment departments in Chinese hospitals;The Breast;2024-10